Quidel Corp (QDEL) Tops Q4 EPS by 20c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Quidel Reports Fourth Quarter and Full Year 2018 Financial Results
February 13, 2019 4:10 PM ESTSAN DIEGO--(BUSINESS WIRE)-- Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the fourth quarter and year ended December31, 2018.
Fourth Quarter 2018 Highlights:
Total revenue grew 15% to $132.6 million as compared to $114.9 million in the fourth quarter of 2017. Quidels legacy revenue grew 3% from the fourth quarter of 2017 to $69.6 million. Total influenza revenue increased 4% from the fourth quarter of 2017 to $34.9 million. Cardiac Immunoassay revenue grew 34% from the fourth... More